linjc16/ctgov huggingface dataset:
Factors Associated With Continuation of Exclusive Breastfeeding Until the Post-natal Visit

Study Overview
=================
Brief Summary
-----------------
Breastfeeding promotes the health of mother and her child, and remains the reference in terms of infant nutrition. World Health Organization recommends exclusive breastfeeding for the first six months. This recommended duration is not respected in France with a median duration of breastfeeding in France at 3 months.

Detailed Description
-----------------
The aim is to study factors associated with continuation of exclusive breastfeeding until the post-natal visit.

Official Title
-----------------
Factors Associated With Continuation of Exclusive Breastfeeding Until the Post-natal Visit

Conditions
-----------------
Breastfeeding

Intervention / Treatment
-----------------
* Other: data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: primiparous and multiparous women women who have initiate breastfeeding women aged 18 and more agreeing to participate in the study Exclusion Criteria: women whose newborn has been in intensive care unit women with a multiple pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| exclusive breastfeeding group<br>Women initiating exclusive breastfeeding after birth | Other: data collection<br>* continuation of exclusive breastfeeding until the post-natal visit (6 to 8 weeks after birth)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| breastfeeding | number of women practicing or not exclusive breastfeeding until postnatal consultation (6 to 8 weeks after birth) | Day 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
exclusive breastfeeding, postnatal visit, factors associated
Peripheral Reading

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate reading performance in the visual periphery by simulating central vision loss using a computer-controlled gaze-contingent display with an eye tracker. Participants will read a page of text at a comfortable rate. Several manipulations hypothesized to improve reading will be tested, such as an inverted-text spotlight of a single word that follows the participant's gaze.

Detailed Description
-----------------
Participants will view paragraphs of multiple sentences of text with their central vision blocked computationally with a simulated scotoma. Participants will be free to move their eyes around the page of text at a comfortable rate. The three outcomes described elsewhere will be evaluated. In different blocks, text will contain one or more of several dynamic assistive manipulations that are hypothesized to enhance reading: 1) inverting the text at a given position, with instructions for the participant to attend to that location, which simulates a surrogate fovea of a patient with central vision loss. 2) horizontally expanding text to alleviate within-word crowding. 3) highlighting the next word with a visible indicator to encourage proper eye movements.

Official Title
-----------------
Factors Limiting Peripheral Reading

Conditions
-----------------
Central Visual Impairment

Intervention / Treatment
-----------------
* Behavioral: Gaze-contingent text enhancement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal vision English language Exclusion Criteria: Less than 20/20 vision in either eye Abnormalities which affect vision (amblyopia, keratoconus, etc.) Ortho-K lenses
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single Arm<br>Each participant will participate in several blocks (randomized order), to evaluate performance with and without behavioral gaze-contingent text enhancements. | Behavioral: Gaze-contingent text enhancement<br>* In different testing blocks, the efficacy of the different enhancements will be evaluated, such as inverting the text in a gaze-contingent inverted spotlight.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reading speed | Average time/word it takes to read a paragraph of text. | From enrollment to completion of testing (<2 weeks) | 
| Reading accuracy | Ability to correctly answer comprehension questions or orally read words | From enrollment to completion of testing (<2 weeks) | 
| Efficiency of eye movement | Ability to move the eyes systematically from word to word | From enrollment to completion of testing (<2 weeks) |
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Taxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens. The main purpose of this research study is to determine if Aptosyn, when given in combination with Taxotere, will result in prolonged survival when compared to Taxotere alone. This study will also help determine tumor response rates, and the safety profile of Aptosyn in combination with Taxotere. This study has been completed and a publication is pending.

Official Title
-----------------
A Phase III, Randomized, Double-Blind, Multi-Center Study of the Efficacy of Taxotere (Docetaxel) in Combination With Aptosyn (Exisulind) Versus Taxotere (Docetaxel) and Placebo in Non-Small Cell Lung Cancer (NSCLC) Patients After Failure of Prior Platinum-Based Chemotherapy

Conditions
-----------------
Non-Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: Exisulind


Participation Criteria
=================
Eligibility Criteria
-----------------
Exclusion Criteria:

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Exisulind|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung Cancer, NSCLC, Non-small Cell Lung Cancer
Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children

Study Overview
=================
Brief Summary
-----------------
Children due for elective eye surgery in propofol based anesthesia will be kept at steady state propofol infusion for maintenance, ventilation via endotracheal tube. Exhaled propofol will be measured continously by Edmon (R) (BBraun) monitor and compared with arterial plasma samples of propofol, drawn 3-5 times during the procedure.

Detailed Description
-----------------
The primary objective of the study is to determine the correlation between simultaneous concentrations of propofol in plasma and expiratory air in children during general anesthesia. Key secondary objectives include correlating plasma and exhaled measurements of propofol with electroencephalogram (BIS) values and computer estimated propofol concentrations in plasma and brain (TCI: target control infusion) Primary endpoint: Exhaled air and plasma concentration ratios of propofol during general anesthesia in children.

Official Title
-----------------
Propofol in Expiratory Air, a Comparison With Plasma Propofol, BIS Value and Calculated Plasma Concentration During General Anesthesia in Children

Conditions
-----------------
Eye Diseases

Intervention / Treatment
-----------------
* Device: Edmon


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elective eye surgey Exclusion Criteria: known propofol hypersensitivity

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Interventional Model Description: Consecutive patients will participate in the study
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: propofol<br>propofol general anesthesia, exhaled measurement of propofol | Device: Edmon<br>* New device for exhaled propofol concentration measurements<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Propofol plasma concentration versus simultaneous exhaled concentration | repeated blood samples of propofol concentration | 5 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Propofol exhaled correlation versus Bispectral Index value (BIS) | repeated blood samples of propofol concentration | 5 hours |
Comparisons of the Astigmatic Power of Toric Intraocular Lens Using Three Toric Calculators: AcrySof, TECNIS, and iTrace Toric Calculator

Study Overview
=================
Brief Summary
-----------------
Purpose of this study is to compare the astigmatic power of the toric IOL obtained from the AcrySof toric calculator, TECNIS toric calculator, and iTrace toric calculator in a group of patients with preoperative with-the-rule (WTR) and against-the-rule (ATR) corneal astigmatism. The study included 100 eyes with cataract and greater than 0.75 diopter of corneal astigmatism, and the subjects were divided into WTR and ATR group. Keratometric value was measured using autokeratometry, IOLMaster partial coherence interferometry (PCI), iTrace incorporating corneal topography and ray-tracing aberrometry. Based on measured values, toric IOL power calculations were performed using AcrySof, TECNIS and iTrace toric calculators.

Conditions
-----------------
Cataract, Astigmatism

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who planned to undergo cataract removal by phacoemulsification Subjects with preoperative corneal astigmatism greater than 0.75 D, as determined by autokeratometry Exclusion Criteria: Subjects with more than 2.74 D of corneal keratometric value from autokeratometry a history of intraocular or corneal surgery and ocular trauma biomicroscopic evidence of corneal disease that could affect corneal astigmatisms contact lens wearer

Ages Eligible for Study
-----------------
Minimum Age: 33 Years
Maximum Age: 87 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| a WTR corneal astigmatism group<br>Corneal astigmatism was defined as WTR when the steep corneal cylinder axis was within 30 degrees of the horizontal axis. | |
| an ATR corneal astigmatism group<br>Corneal astigmatism was defined as ATR when the cylinder axis was within 30 degrees of the vertical axis. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference of toric intraocular lens power between three toric calculators | Comparison of the toric intraocular lens power calculated from Acrysof and TECNIS toric calculators using keratometric values measured by autokeratometry or IOLMaster PCI and that from iTrace toric calculator with keratometric value measurement using iTrace ray tracing wavefront aberrometry and iTrace simulated keratometry. | Immediately after measurement | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
toric calculator, toric intraocular lens power, Acrysof, Tecnis, iTrace
Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe. The aim of this observational study is to evaluate the glycaemic control, weight change and hypoglycaemic effects in patients with type 2 diabetes with Levemir® compared to Insulatard® under normal clinical practice conditions.

Official Title
-----------------
Efficacy and Safety of Glycaemic Control of Levemir® or Insulatard® in Patients With Type 2 Diabetes

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: insulin detemir
* Drug: insulin NPH


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes failing on oral blood glucose lowering therapy, and requiring insulin therapy. Exclusion Criteria: Type 1 diabetes Previous use of insulin
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br> | Drug: insulin detemir<br>* Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician<br>|
| B<br> | Drug: insulin NPH<br>* Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body weight change |  | at 3 months and 6 months after baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hypoglycemic events |  | at 3 months and 6 months after baseline | 
| Changes in glycaemic parameters |  | at 3 months and 6 months after baseline | 
| Safety parameters by collecting (serious) adverse events and the pregnancies. |  | at 3 months and 6 months after baseline | 
| Evaluation of general well-being by using the WHO-5 well-being questionnaire (Appendix I). |  | at 3 months and 6 months after baseline | 
| Treatment satisfaction of subjects treated with insulin Levemir or NPH insulin by using insulin satisfaction ('Tevredenheid met insuline behandeling': Appendix II) |  | at 3 months and 6 months after baseline | 
| Satisfaction of physicians who treat the subjects with insulin Levemir or NPH in-sulin by using a scale of 0-10 (Appendix III). |  | at 3 months and 6 months after baseline | 
| Changes in doses |  | at 3 months and 6 months after baseline | 
| HbA1c |  | at 3 months and 6 months after baseline | 
| Changes in daily blood glucose values |  | at 3 months and 6 months after baseline |
Earliest Lung Ultrasound Time for Predicting the Need of Surfactant

Study Overview
=================
Brief Summary
-----------------
Lung ultrasonography (LUS) is fast and easy technique. it also has high reliability, so it has started to be used more in evaluating respiratory distress in the neonatal period. The most important feature of LUS is being radiation-free. Three LUS findings that show respiratory distress syndrome were described. They were white lung appearance, lack of preserved areas and loss of pleural integrity. The sensitivity of these findings was found to be 98-100% and the specificity 92-100%. A few studies have shown that surfactant need can be determined by LUS. It was observed that lung findings were more severe in LUS performed in the early period because of non-completed fetal lung fluid clearence, but the findings could be improved during follow-up. Therefore, it is not known when the earliest time of LUS shows the actual clinical condition and course of the patient. This study was planned to find the most reliable and earliest US time. Evaluation with LUS was done at 30 minutes and repeated at 1, 2, 4 and 6 hours of life. The LUS findings would be compared with x-ray findings and the correlation of surfactant need with LUS findings would also be investigated.

Official Title
-----------------
Earliest Lung Ultrasound Time for Predicting the Need of Surfactant

Conditions
-----------------
Respiratory Distress Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: lung ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: preterm babies with a gestational age 32 weeks or less babies treated with CPAP Exclusion Criteria: If a baby was intubated in delivery room because of the responsiveness to face-mask ventilation, he/she was excluded. congenital heart diseases complex congenital malformations chromosomal abnormalities.

Ages Eligible for Study
-----------------
Minimum Age: 30 Minutes
Maximum Age: 6 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: lung ultrasound|LUS was performed within first 20 to 30 minutes and repeated at 1, 2, 4 and 6 hours.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lung ultrasound at 30 minutes | lung ultrasound findings | 30 minutes | 
| lung ultrasound at 1 hour | lung ultrasound findings | 1 hour | 
| lung ultrasound at 2 hour | lung ultrasound findings | 2 hour | 
| lung ultrasound at 4 hour | lung ultrasound findings | 4 hour | 
| lung ultrasound at 6 hour | lung ultrasound findings | 6 hour |
Morphine for the Treatment of Pain in Patients With Breast Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Morphine helps to relieve the pain associated with cancer surgery. Giving morphine in different ways may offer more pain relief. PURPOSE: This randomized clinical trial is studying how well morphine injected directly into the underarm area works compared with morphine injected into the back of the shoulder in treating pain in patients who have breast cancer and who are undergoing axillary lymph node dissection.

Detailed Description
-----------------
OBJECTIVES: I. Determine whether morphine injected at the site of surgery can control pain from surgery. OUTLINE: This is a prospective, double blind, randomized study. Patients are randomized into 3 groups with 6 patients in each group. Group 1 receives morphine diluted in normal saline (NS), which is administered in the axillary region at the completion of surgery before surgical closure. The area is flooded and the solution is allowed to remain in the wound for 5 minutes. Group 2 (control group) receives NS only, administered in the same fashion as group 1. Group 3 receives morphine subcutaneously in the deltoid area, ipsilateral to the site of surgery, at the beginning of wound closure. Postoperatively, patients self-administer IV fentanyl analgesia through a patient controlled analgesia pump. Comparisons of daily IV fentanyl utilization is done among the three groups. Quality of pain is assessed via visual analog pain scores four times a day at 2, 4, 6, and 24 hours postoperatively. PROJECTED ACCRUAL: A total of 18 patients will be accrued over a period of 2 years.

Official Title
-----------------
Peripheral Effects of Opioid Analgesia in Patients Undergoing Axillary Node Dissection

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: fentanyl citrate
* Drug: morphine sulfate


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Patients with breast cancer who are scheduled to undergo axillary node dissection PATIENT CHARACTERISTICS: See General Eligibility Criteria PRIOR CONCURRENT THERAPY: No oral-equivalent doses of morphine greater than 10 mg a day -- Patient Characteristics-- Age: Not specified Sex: Not specified Other: Not allergic to morphine

Ages Eligible for Study
-----------------
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: fentanyl citrate|nan|
|Drug: morphine sulfate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain
Cardiotoxicity of Aluminum Phosphide Poisoning; Tropinin and CKmb as Early Biomarkers

Study Overview
=================
Brief Summary
-----------------
Aluminum phosphide (AlP) or rice tablet is a cheap pesticide. When it comes in contact with acid (gastric acid) or moisture, it releases phosphine (PH3) gas. The heart,lungs, liver are the main targets in acute Aluminum phosphide (AlP) poisoning. Most deaths occur due to cardiovascular toxicity.

Detailed Description
-----------------
Aluminium phosphide is a potent respiratory chain enzyme inhibitor. Its most important effect is the inhibition of cytochrome c oxidase. The inhibition of cytochrome c oxidase and other enzymes leads to the generation of superoxide radicals and cellular peroxides , and subsequent cellular injury through lipid peroxidation and other oxidant mechanisms. It stimulates the production of hydrogen peroxide and reactive oxygen species, malonyldialdehyde (MAD), increases superoxide dismutase and inhibits catalase, peroxidase and glutathione . Oxidative stress is one of the main mechanisms of action of aluminium phosphide toxicity

Official Title
-----------------
Cardiotoxicity of Aluminum Phosphide Poisoning; Biochemical and Electrophysiological Studies and the Utility of Tropinin and CKmb as Early Biomarkers

Conditions
-----------------
Cardiotoxicity, Aluminum Phosphid Poisoning

Intervention / Treatment
-----------------
* Diagnostic Test: serum tropinin, serum CKmb


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ALP poisoned cases admitted with free ECG Exclusion Criteria: concomitant ingesion of other drugs or toxins -
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: serum tropinin, serum CKmb|early detection of myocardial injury, allowing application of acute cardiac shock and cardiogenic shock|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| assess serum tropinin and CKmb as biomarkers for early detection of ALP induced myocardial injury | assess serum tropinin and CKmb as biomarkers for early detection of ALP induced myocardial injury | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tropinin, CKmb, cardiotoxicity